A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/00 (2006.01) A61K 38/17 (2006.01) A61K 38/44 (2006.01)
Patent
CA 2480883
The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)- biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR- biologically active agent fusion has substantially increased serum half-life.
la présente invention concerne un moyen d'accroître la demi-vie sérique d'un agent biologiquement actif précis faisant intervenir la transthyrétine (TTR) comme partenaire de fusion avec ledit agent. Cette invention concerne spécifiquement des préparations homogènes de fusions d'agent biologiquement actif-TTR (ou variante de TTR) et de fusions d'agent biologiquement actif-PEG-TTR (variante PEG-TTR). Comparée à l'agent biologiquement actif seul, la fusion agent biologiquement actif-TTR et/ou la fusion agent biologiquement actif-PEG-TTR présente une demi-vie sérique sensiblement accrue.
Walker Kenneth
Xiong Fei
Amgen Inc.
Gowling Lafleur Henderson Llp
LandOfFree
Use of transthyretin peptide/protein fusions to increase the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of transthyretin peptide/protein fusions to increase the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of transthyretin peptide/protein fusions to increase the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2065511